Allied Market Research


Capecitabine Market

Capecitabine Market Size, Share, Competitive Landscape and Trend Analysis Report by Application and by Drug Formulation : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Capecitabine is a chemotherapy drug that acts by reducing or preventing the progression of cancer cells. This drug is used for the treatment of cancers such as colorectal cancer, breast cancer, and gastric cancer.

Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of capecitabine drive the growth of the capecitabine market. According to the National Cancer Institute around 135,430 people are estimated to suffer from colon and rectum cancer and 50,260 people died of colon and rectum cancer in 2017 in the U.S. Furthermore, rise in healthcare expenditure and increase in investment in cancer treatment or assisted programs by governments and private organizations such as Cancer Care and Cancer Suraksha Scheme are anticipated to boost the market growth. However, high cost of capecitabine, adverse effects, presence of substitutes, such as raltitrexed and leucovorin, and stringent government regulations related to the safety and efficacy of capecitabine hinder the market growth. Ongoing R&D activities related to capecitabine are anticipated to present new opportunities for the market.

The market is segmented on the basis of application, drug formulation, and geography. Based on application, the market is categorized into colon cancer, rectal cancer, breast cancer, gastric cancer, and others. By drug formulation, it is bifurcated into tablets and capsules. The geographical breakdown of each of the aforesaid segment is covered for North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global capecitabine market with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis to help the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

Capecitabine Market Report Highlights

Aspects Details
By Application
  • Colon Cancer
  • Rectal Cancer
  • Breast Cancer
  • Gastric Cancer
  • Others
By Drug Formulation
  • Tablets
  • Capsules
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Sandoz, Ranbaxy Laboratories Ltd., Genentech, Inc., Cipla Inc., F. Hoffmann-La Roche, Dr Reddy Laboratories Ltd, Accord Healthcare Ltd., Teva Pharma B.V., Zentiva N.V., Fresenius SE & Co. KGaA

Loading Table Of Content...

Capecitabine Market

Global Opportunity Analysis and Industry Forecast, 2023-2032